Not Yet Recruiting INTERVENTIONAL NCT07557225

18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors

Evaluation of Diagnostic Value of 18F-T2 PET/ CT Imaging for Tumors Likely to Express High Levels of CAIX

Sponsor: Peking University First Hospital

Conditions Breast Cancer Cervical Cancer Cholangiocarcinoma Clear Cell Renal Cell Cancer (ccRCC) Colorectal Cancer Endometrial Cancer Head and Neck Cancer Hepatocellular Carcinoma (HCC) Non Small Cell Lung Cancer Ovarian Cancer Pancreatic Cancer Small Cell Lung Cancer Urothelial Carcinoma (UC) Von Hippel Lindau Disease

Interventions 18F-T2 PET/CT

Updated 1 time since 2026 Last updated: Apr 22, 2026 Started: Apr 1, 2026 Primary completion: Sep 1, 2028 Completion: Mar 1, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Breast Cancer and Cervical Cancer and is currently actively recruiting participants. Peking University First Hospital leads this study, which shows 1 recorded version since 2026 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

1 version recorded

Not Yet Recruiting [daily]

Eligibility Summary

The goal of this clinical trial is to evaluate the diagnostic value of CAIX protein specific probe 18F-T2 in PET/CT imaging in participants with solid tumors. It will also assess the safety, tolerability and radiation dosimetry of 18F-T2.

Contact Information

Sponsor contact:

Peking University First Hospital

Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China